Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Invested Capital (2019 - 2025)

Historic Invested Capital for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $946.3 million.

  • Kymera Therapeutics' Invested Capital rose 597.22% to $946.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $946.3 million, marking a year-over-year increase of 597.22%. This contributed to the annual value of $835.6 million for FY2024, which is 11156.46% up from last year.
  • Per Kymera Therapeutics' latest filing, its Invested Capital stood at $946.3 million for Q3 2025, which was up 597.22% from $971.5 million recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Invested Capital ranged from a high of $971.5 million in Q2 2025 and a low of $258.1 million during Q2 2021
  • For the 5-year period, Kymera Therapeutics' Invested Capital averaged around $569.6 million, with its median value being $483.1 million (2021).
  • As far as peak fluctuations go, Kymera Therapeutics' Invested Capital skyrocketed by 39343.09% in 2021, and later tumbled by 2288.04% in 2023.
  • Kymera Therapeutics' Invested Capital (Quarter) stood at $459.6 million in 2021, then grew by 6.64% to $490.2 million in 2022, then decreased by 19.42% to $395.0 million in 2023, then skyrocketed by 111.56% to $835.6 million in 2024, then rose by 13.24% to $946.3 million in 2025.
  • Its last three reported values are $946.3 million in Q3 2025, $971.5 million for Q2 2025, and $786.2 million during Q1 2025.